Biocon Biologics successfully completes integration of acquired biosimilars business in 120 countries
Biocon Biologics  /  Stories  /  Biocon Biologics successfully completes integration of acquired biosimilars business in 120 countries

Biocon Biologics successfully completes integration of acquired biosimilars business in 120 countries

Biocon Biologics has successfully completed the final phase of integration of the acquired global biosimilars business from Viatris, a year ahead of schedule. In this phase, over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned to Biocon Biologics.

The integration of the acquired business is an important milestone for Biocon Biologics in our journey to become a global biosimilars leader. Full integration across the biosimilars value chain from lab to market significantly expands our reach.

All Viatris’ biosimilars brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart) are now part of Biocon Biologics’ commercial franchise in Advanced Markets and over 80 Emerging Markets. Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia.

Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the U.S., Canada, Europe and 9 key Emerging Market countries of India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.

A direct presence in these markets will enable us to get closer to patients and strengthen our relationships with prescribers and payers. It will also allow us to expand our patient reach and generate significant savings for healthcare systems.

With this acquisition Biocon Biologics emerges as a world leading biosimilars player.

“I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries. The conclusion of this final wave of transition is a significant milestone and marks the beginning of Biocon Biologics’ transformation to a fully integrated global company. I congratulate and thank the entire Biocon Biologics team – colleagues, advisors, and partners. This seamless transition, achieved ahead of schedule, is an outcome of relentless focus, untiring efforts and an unwavering commitment to patients and business continuity.”

Shreehas Tambe
CEO & Managing Director, Biocon Biologics Ltd

Making a difference in Emerging Markets

Addressing the unmet needs of patients worldwide is at the core of our overarching purpose of ushering in transformational change to global healthcare.

Non-communicable diseases (NCDs) such as cancer and diabetes are the leading public health challenge in developing countries, with Low- and Middle-Income Countries (LMICs) being the worst-affected. According to the World Health Organization, 77% of all NCD deaths occur in LMICs. As a unique, fully integrated ‘lab to market’ global biosimilars company, Biocon Biologics is perfectly positioned to address this health inequity and provide affordable access to advanced therapies.


Our high-quality biosimilar insulins are already providing a much-needed affordable option to patients in many Emerging Markets, with Recombinant Human Insulin and Insulin Glargine holding dominant market shares in countries such as Mexico, Malaysia, Dominican Republic, Malawi, Tanzania and Mozambique. Our cancer portfolio compromising Trastuzumab, Bevacizumab and Pegfilgrastim are making a difference to the lives of patients in several APAC, AFMET and LATAM countries.


We have been able to build credibility as a serious biosimilar player among patients and prescribers in the Emerging Markets, given our over two decades of experience in this domain.

With the acquisition bringing us complementary capabilities, including a direct presence and related infrastructure in the Emerging Markets, we will now be able to ensure ‘last mile’ delivery and expand access to biosimilars for treating NCDs such as cancer and diabetes.

In doing so, we could not only help save millions of lives worldwide, but also move the world closer to achieving the United Nations Sustainable Development Goal (UN SDG) 3.4 of reducing premature mortality from NCDs by a third by 2030.

Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models to ensure business continuity for patients, prescribers, partners, and healthcare systems.

Integration Completed Ahead of Schedule

During the acquisition of Viatris’ biosimilars business in November 2022, we had entered into a transition services agreement with our long-term partner for ongoing operational services for a period of two years to complete the integration in a phased manner.

Our belief in our capabilities led us to prepare a comprehensive transition plan and successfully conclude the integration process a year ahead of schedule


“The completion of the integration marks a key milestone in Biocon Biologics’ transformational journey towards becoming a global biosimilars leader. This presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model in key Emerging Markets will take us closer to the patients, MoHs, prescribers and payers. It will allow us to expand affordable access to larger patient pools in these Emerging Markets, thus enabling equitable access to high quality biosimilars.”

Susheel Umesh
Chief Commercial Officer – Emerging Markets
Biocon Biologics

On July 1, 2023, we successfully integrated over 70 countries in Emerging Markets into Biocon Biologics. This successful integration gave us the confidence to accelerate the transition of North America and Europe. The integration of the business in North America (United States and Canada) was done in September, and three months later, on November 30, 2023, we finished the transition in 31 countries in Europe.

The acquisition is an inflection point in our journey and is designed to create a global leader in biosimilars and maximize value for all our stakeholders. Our end-to-end capabilities, unique portfolio, and the consolidation of the acquired business set us up for success and provide a runway to sustainable, profitable growth.

“We are extremely pleased to have reached this historic moment and are proud to say that biosimilars are not just what we do – they are all that we do. With the successful completion of the integration, we will be providing patients, customers, and healthcare providers in North America, Europe and JANZ a strong portfolio of biosimilars. Our deep expertise, commitment to continual investment to advance biosimilars throughout the value chain from development, manufacturing, distribution and commercialization makes us a trusted partner.”

Matthew Erick
Chief Commercial Officer – Advanced Markets
Biocon Biologics Ltd

buy twitter followers